arrow
C

Carmine Rossi

analysis group inc.
H指数:21
被引数:1,317

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-world comparative effectiveness of apalutamide versus enzalutamide for prostate-specific antigen response in metastatic castration-sensitive prostate cancer

阿帕卢他胺与恩扎卢他胺在转移性去势敏感前列腺癌中前列腺特异性抗原反应的实世界比较有效性

2026-05-210
PRE
QUALITY CARE MEASURES AMONG PATIENTS WITH HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER WITH PAPILLARY CARCINOMA OR CARCINOMA IN SITU RECEIVING FRONT-LINE BACILLUS CALMETTE-GUÉRIN OR OTHER INTRAVESICAL THERAPIES

高风险非肌层浸润性膀胱癌(伴乳头状癌或原位癌)患者接受一线卡介苗或其他膀胱内治疗时的护理质量评估

2026-05-010
PRE
Homologous Recombination Repair Mutations, Next-generation Sequencing Testing, and Treatment Progression by Race Among Patients With Metastatic Castration-sensitive Prostate Cancer

同源重组修复突变、下一代测序检测及不同种族转移性去势敏感前列腺癌患者的治疗进展

2026-05-010
PRE
Comparison of deep prostate-specific antigen response in Black patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or enzalutamide

比较黑种人转移性去势敏感前列腺癌患者使用阿帕鲁amide或恩扎鲁amide治疗的深度前列腺特异性抗原反应

2026-01-010
PRE
Real-World Comparison of On-Label Treatment Persistence Through 24 Months Between Patients with Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Interleukin-17A Inhibitors

真实世界研究中,在24个月内比较起始使用Guselkumab或皮下注射白介素-17A抑制剂治疗银屑病关节炎患者的标签内治疗持续性。

2025-11-210
OAAI
On-Label Treatment Persistence Through 24 Months Among Patients with Active Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Tumor Necrosis Factor Inhibitors

24个月内活动性银屑病关节炎患者使用古塞库单抗或皮下肿瘤坏死因子抑制剂的标签内治疗持续性

2025-11-140
OAAI
Time and cost burden associated with docetaxel in patients with metastatic castration-sensitive prostate cancer initiating an androgen receptor pathway inhibitor-based regimen

与多西他赛相关的患者负担(时间和成本),这些患者患有转移性去势敏感的前列腺癌,并开始接受以雄激素受体通路抑制剂为基础的治疗方案。

2025-09-280
OAAI
Healthcare resource utilization and costs among patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or enzalutamide in the United States (2019–2023)

2019-2023年间,美国接受阿帕卢他胺或恩扎卢他胺治疗的转移性去势敏感前列腺癌患者的医疗资源利用及费用。

2025-08-100
OA
Elevated risk of colorectal, liver, and pancreatic cancers among HCV, HBV and/or HIV (co)infected individuals in a population based cohort in Canada
2021-02-1110
OAAI